Biotechnology stocks remain one of worst performing areas that are still stuck in a bear market after failing to recuperate earlier losses in the year, along with the broader market. However, exchange traded fund (ETF) investors still believe in a rebound.

The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, declined 17.0% year-to-date and decreased 22.2% over the past year. Meanwhile, IBB has attracted $152.5 in net inflows year-to-date, according to ETF.com.

“Biotechs took such a beating that it still needs to catch up,” David Fajardo, Senior Vice President of Direxion Investments, told ETF Trends in a call.

Biotechnology has finally stumbled as outperforming growth stocks took a hit earlier this year. The sector has previously been outperforming during the bull market rally, with IBB showing an average annual return of 21.9% over the past five years, compared to the S&P 500’s return of 5.4%.

“Many were thinking it was overbought, but now many think it is oversold,” Fajardo added.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.